Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2935-2944

  Goossens Beumer, I J ^a   Zeestraten, E C M ^a   Benard, A ^a   Christen, T ^a   Reimers, M S ^a   Keijzer, R ^a   Sier, C F M ^a   Liefers, G J ^a   Morreau, H ^a   Putter, H ^a   Vahrmeijer, A L ^a   Van De Velde, C J H ^a   Kuppen, P J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ALDH1A1 protein; Biomarkers; BIRC5 protein; Cancer hallmarks; Colon neoplasms; EPCAM protein; Recurrence; Survival analysis

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; EPITHELIAL CELL ADHESION MOLECULE; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; COLON CANCER; COLORECTAL CANCER; DISEASE SPECIFIC SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TUMOR RECURRENCE;

AGED; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RETINAL DEHYDROGENASE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902548792     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.226     Document Type: Article

References (52)

1. Altieri DC (1994) Splicing of effector cell protease receptor-1 mRNA is modulated by an unusual retained intron. Biochemistry 33(46): 13848-13855
2. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-Apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8): 917-921. (Pubitemid 27353455
3. Balzar M, Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV (1999) The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 246(1): 108-121. (Pubitemid 29393751
4. Basak S, Speicher D, Eck S, Wunner W, Maul G, Simmons MS, Herlyn D (1998) Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst 90(9): 691-697. (Pubitemid 28222143
5. Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van CE, Brouwers M, Charette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16): 3408-3419. (Pubitemid 41103700
6. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, Orntoft TF (2005) Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 54(3): 374-384. (Pubitemid 40299094
7. Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB (2012) Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 105(6): 520-528
8. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, McDonnell DP (2006) Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 103(31): 11707-11712. (Pubitemid 44182515
9. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del BR, Strazzer S, Bresolin N, Comi GP (2006) Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 24(4): 975-985. (Pubitemid 44464730
10. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L, Sturgeon C (2013) Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 134(11): 2513-2522
11. Duffy MJ, van DA, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43(9): 1348-1360. (Pubitemid 46874070
12. Duffy MJ, van DA, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (2003) Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39(6): 718-727. (Pubitemid 36315986
13. Edwards DP, Grzyb KT, Dressler LG, Mansel RE, Zava DT, Sledge Jr GW, McGuire WL (1986) Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res 46(3): 1306-1317. (Pubitemid 16048272
14. Gosens MJ, van Kempen LC, van De Velde CJ, van Krieken JH, Nagtegaal ID (2007) Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 20(2): 221-232. (Pubitemid 46422177
15. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, Beaumont C, Clark-Langone KM, Yoshizawa CN, Lee M, Watson D, Shak S, Kerr DJ (2011) Validation study of a quantitative multigene reverse transcriptasepolymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29(35): 4611-4619
16. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28(2): 264-271
17. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1): 57-70. (Pubitemid 30046295
18. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5): 646-674
19. Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76(3): 1438-1442. (Pubitemid 9136880
20. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69(8): 3382-3389
21. Kahlert C, Gaitzsch E, Steinert G, Mogler C, Herpel E, Hoffmeister M, Jansen L, Benner A, Brenner H, Chang-Claude J, Rahbari N, Schmidt T, Klupp F, Grabe N, Lahrmann B, Koch M, Halama N, Buchler M, Weitz J (2012) Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy. Ann Surg Oncol 19(13): 4193-4201
22. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58(22): 5071-5074. (Pubitemid 28521163
23. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumourigenesis. Cancer 91(11): 2026-2032. (Pubitemid 32476366
24. Kelley RK, Van Bebber SL, Phillips KA, Venook AP (2011) Personalized medicine and oncology practice guidelines: A case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw 9(1): 13-25
25. Komuro K, Tada M, Tamoto E, Kawakami A, Matsunaga A, Teramoto K, Shindoh G, Takada M, Murakawa K, Kanai M, Kobayashi N, Fujiwara Y, Nishimura N, Hamada J, Ishizu A, Ikeda H, Kondo S, Katoh H, Moriuchi T, Yoshiki T (2005) Right-And left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. J Surg Res 124(2): 216-224. (Pubitemid 40463721
26. Lassmann S, Tang L, Capanu M, Brabletz T, Schopflin A, Zur HA, Gonen M, Kemeny N, Shia J, Klimstra D, Werner M (2007) Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy. Gastroenterology 133(6): 1831-1839. (Pubitemid 350180803
27. Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG, Ma T (2003) Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol 9(5): 974-977. (Pubitemid 36681663
28. Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, Warnaar SO (1994a) Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 2(5): 417-428. (Pubitemid 24351019
29. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994b) Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125(2): 437-446. (Pubitemid 24135956
30. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast Jr RC (2006) ASCO 2006 update of recommendations for the use of tumour markers in gastrointestinal cancer. J Clin Oncol 24(33): 5313-5327. (Pubitemid 46631379
31. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I (2010) Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 103(3): 382-390
32. Maak M, Simon I, Nitsche U, Roepman P, Snel M, Glas AM, Schuster T, Keller G, Zeestraten E, Goossens I, Janssen KP, Friess H, Rosenberg R (2013) Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 257(6): 1053-1058
33. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer 93(4): 387-391. (Pubitemid 43080010
34. Molotkov A, Duester G (2003) Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid. J Biol Chem 278(38): 36085-36090. (Pubitemid 37139929
35. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N (2010) Relationship between tumour gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28(25): 3937-3944
36. Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26(11): 2389-2430. (Pubitemid 46730255
37. Quirke P, Cuvelier C, Ensari A, Glimelius B, Laurberg S, Ortiz H, Piard F, Punt CJ, Glenthoj A, Pennickx F, Seymour M, Valentini V, Williams G, Nagtegaal ID (2010) Evidence-based medicine: The time has come to set standards for staging. J Pathol 221(4): 357-360
38. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65(11): 4881-4887. (Pubitemid 40740827
39. Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K, Schick C, Sauer R, Rodel C (2002) High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178(8): 426-435. (Pubitemid 34847422
40. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van d V, Morreau H, Van VL, Glas AM, Van't Veer LJ, Tollenaar R (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29(1): 17-24
41. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46(5): 645-650. (Pubitemid 30305781
42. Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P (2011) EpCAM expression in primary tumour tissues and metastases: An immunohistochemical analysis. J Clin Pathol 64(5): 415-420
43. Sprenger T, Rodel F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K, Wolff HA, Ghadimi BM, Yildirim M, Becker H, Rodel C, Liersch T (2011) Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 17(6): 1623-1631
44. van Der Gun BT, Melchers LJ, Ruiters MH, De Leij LF, McLaughlin PM, Rots MG (2010) EpCAM in carcinogenesis: The good, the bad or the ugly. Carcinogenesis 31(11): 1913-1921
45. von Eitzen U, Meier-Tackmann D, Agarwal DP, Goedde HW (1994) Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. Cancer Lett 76(1): 45-49. (Pubitemid 24051646
46. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94(1): 128-135. (Pubitemid 43088552
47. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35(1): 122-128. (Pubitemid 38133932
48. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C (2003) Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 9(3): 931-946. (Pubitemid 36323695
49. Xiaoyuan C, Longbang C, Jinghua W, Xiaoxiang G, Huaicheng G, Qun Z, Haizhu S (2010) Survivin: A potential prognostic marker and chemoradiotherapeutic target for colorectal cancer. Ir J Med Sci 179(3): 327-335
50. Yoshida A, Hsu LC, Dave V (1992) Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 46(4-5): 239-244. (Pubitemid 23047772
51. Zeestraten EC, Maak M, Shibayama M, Schuster T, Nitsche U, Matsushima T, Nakayama S, Gohda K, Friess H, van De Velde CJ, Ishihara H, Rosenberg R, Kuppen PJ, Janssen KP (2012) Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer 106(1): 133-140
52. Zeestraten EC, Reimers MS, Saadatmand S, Dekker JW, Liefers GJ, van den Elsen PJ, van De Velde CJ, Kuppen PJ (2014) Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer 110(2): 459-468.